Health
Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association's annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25 mg was associated with significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison1. It is important to note that the FDA recently approved orforglipron under the brand name Foundayo™ at doses ranging up to 17.2 mg.3 The approved 17.2 mg tablet is the equivalent to the orforg
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"Treatment with orforglipron 36 mg was associated with ~14 times higher odds of stopping medication due to GI adverse events versus oral semaglutide 25 mg in the ITC1","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"In a separate patient preference study, 84% of survey respondents favored the treatment profile similar to oral semaglutide 25 mg compared to that similar to orforglipron2","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":553,"olType":false},{"type":"text","content":"PLAINSBORO, N.J. and BAGSVÆRD, Denmark, April 2, 2026 /PRNewswire/ -- Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association's annual conference in San Diego showing that Wegovy® (semaglutide) tablets 25 mg was associated with significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison1. It is important to note that the FDA recently approved orforglipron under the brand name Foundayo™ at doses ranging up to 17.2 mg.3 The approved 17.2 mg tablet is the equivalent to the orforglipron 36 mg capsules used in phase 3 trials, and which served as the study comparator in ORION.1,4 Additionally, in a separate patient preference study, adults with overweight or obesity showed greater preference for an oral semaglutide-like profile than an orforglipron-like profile.2 These findings suggest potential differentiation and provide valuable insights to inform clinical decision-making.1 ","length":976,"tagName":"p"},{"type":"text","content":""These studies add to the growing body of evidence supporting the clinical strength of semaglutide and highlight attributes that patients value when choosing an obesity medicine that fits their lifestyle," said Jamey Millar, executive vice president, US Operations of Novo Nordisk. "Since its approval, we've seen strong interest in Wegovy® pill, from both healthcare professionals and people seeking obesity therapy, underscoring the importance of our continued focus on advanc...